Hi Welcome You can highlight texts in any article and it becomes audio news that you can hear
  • Tue. Nov 5th, 2024

Merck to buy Austrian vaccine maker as it jumps into COVID-19 race

Byindianadmin

May 26, 2020 #Covid-, #jumps
Merck to buy Austrian vaccine maker as it jumps into COVID-19 race

CHICAGO (Reuters) – Merck & Co Inc (MRK.N), which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines.

It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus.

It did not disclose the terms of the acquisition of Themis, a privately held company.

Most big pharmaceutical companies have already placed their bets on COVID-19 treatments, but Merck has been waiting for opportunities with proven track records, Chief Executive Ken Frazier said.

“We wanted to be in a position where we could choose things that have the right kind of characteristics to make a contribution for a virus that’s likely to be with us for some time,” he told Reuters in an interview.

Both vaccines are designed to be delivered in a single dose.

The Themis vaccine, developed in collaboration with the Institut Pasteur in Paris, is based on a modified measles virus that delivers bits of the SARS-CoV-2 virus into the body to prevent COVID-19.

It was developed in part through funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

Merck said it moving quickly with this candidate and e

Read More

Click to listen highlighted text!